Form 20-F NOVARTIS AG For: Dec 31
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20260204/APBDB22CG222D2Z2222Q22ZZ8BEGZ2G23282
Filed on: February 4, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis DM1 drug trial misses primary endpoint in Phase III study
- Allogenetics Raises €3.8 Million Pre-Series A to Advance Novel Ex Vivo Gene Therapy Approach to Improve Organ Transplantation Outcomes
- CLSA Reiterates Outperform (2) Rating on Novartis (NOVN:SW) (NVS)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
